Skip to main content

Table 2 Therapy and outcomes of EPE postoperative meningitis

From: Phenotype, molecular characterisation and risk factors for postoperative meningitis caused by ESBL-producing-Enterobacteriaceae: a six years multi-Centre comparative cohort study

Antibiotics Total (220) EPE (78) NEPE (142) χ2 P
Antibiotic prophylaxis 210 (95.4%) 73 (93.6%) 133 (93.7%) 0.999
 Ceftazidime 13 (5.9%) 7 (9.0%) 6 (4.2%) 2.055 0.229
 Ceftriaxone 34 (15.4%) 14 (18.0%) 20 (14.1%) 0.589 0.440
 Cefuroxime 109 (49.6%) 38 (48.7%) 71 (50.0%) 0.596 0.460
 Meropenem 9 (4.1%) 3 (3.8%) 6 (4.2%) 0.018 0.999
 Erythromycin 13 (5.9%) 5 (6.4%) 8 (5.6%) 0.055 0.774
 Cefoperazone/Sulbactam 11 (5.0%) 2 (2.6%) 9 (6.3%) 1.512 0.334
 Others 17 (7.7%) 4 (5.1%) 13 (9.2%) 1.148 0.428
Received empirical antibiotics 208 (94.6%) 73 (93.6%) 135 (95.1%) 0.241 0.758
 Single antibiotics 75 (34.1%) 23 (29.5%) 52 (36.6%) 1.010 0.365
 Ceftriaxone 11 (5.0%) 4 (5.13%) 7 (4.9%) 0.197 0.728
 Meropenem 46 (20.9%) 15 (19.2%) 31 (21.8%) 0.211 0.798
 Cefuroxime 4 (1.8%) 1 (1.3%) 3 (2.1%) 0.064 0.999
 Vancomycin 14 (6.4%) 3 (3.8%) 11 (7.8%) 0.691 0.529
 Combination antibiotics (2) 113 (51.4%) 42 (53.8%) 71 (50.0%) 0.466 0.560
 Vancomycin + Meropenem 96 (43.6%) 35 (44.9%) 61 (43.0%) 0.138 0.788
 Vancomycin + Ceftazidime 7 (3.2%) 3 (3.8%) 4 (2.8%) 0.103 0.710
 Others 10 (4.6%) 4 (5.1%) 6 (4.2%) 0.038 0.999
 Combination antibiotics (3) 28 (12.7%) 9 (11.5%) 19 (13.4%) 0.124 0.833
 Vancomycin + Meropenem +Cefuroxime 8 (3.6%) 3 (3.8%) 5 (3.5%) 0.147 0.999
 Vancomycin + Meropenem +Tinidazole 6 (2.7%) 3 (3.8%) 3 (2.1%) 1.116 0.352
Others 14 (6.4%) 3 (3.8%) 11 (7.8%) 1.474 0.420
Received definitive therapy 215 (97.7%) 74 (94.9%) 141 (99.3%) 4.436 0.055
 Single antibiotics 67 (30.4%) 19 (24.4%) 48 (33.8%) 1.584 0.220
 Meropenem 61 (27.7%) 16 (20.5%) 45 (31.7%) 1.519 0.341
 Ceftriaxone 4 (1.8%) 2 (2.6%) 2 (1.4%) 0.981 0.371
 Colistin 2 (0.9%) 1 (1.3%) 1 (0.7%) 0.475 0.490
 Combination antibiotics (2) 128 (58.2%) 48 (61.5%) 80 (56.3%) 1.331 0.306
 Vancomycin + Meropenem 105 (47.7%) 39 (50.0%) 66 (46.5%) 0.032 0.999
 Vancomycin + Ceftazidime 8 (3.6%) 3 (3.8%) 5 (3.5%) 0.001 0.999
 Meropenem + Tigecycline 8 (3.6%) 2 (2.6%) 6 (4.2%) 0.569 0.709
 Others 7 (3.2%) 4 (5.1%) 3 (2.1%) 1.219 0.424
 Combination antibiotics (3) 20 (9.1%) 7 (9.0%) 13 (9.2%) 0.003 0.999
 Colistin+ Meropenem + Trimethoprim 7 (3.2%) 2 (2.6%) 5 (3.5%) 0.196 0.999
 Colistin+ Tigecycline + Meropenem 6 (2.7%) 3 (3.8%) 3 (2.1%) 0.848 0.613
Others 7 (3.2%) 2 (2.6%) 5 (3.5%) 0.196 0.999
Clinical Outcome
 Improved and cured 184 (83.6%) 62 (79.5%) 122 (85.9%) 1.520 0.254
 Mortality attributed to infection 26 (11.8%) 14 (18.0%) 12 (8.4%) 4.358 0.049
 Mortality not attributed to infection 10 (4.6%) 2 (2.6%) 8 (5.6%) 1.093 0.500